Robotic surgery advances in oncology and cardiac care

Robotic surgery is increasingly surpassing traditional and laparoscopic techniques in clinical efficacy, particularly in oncology and cardiac procedures. Recent international studies, including research published in The Lancet Gastroenterology & Hepatology, show that robotic surgery for esophageal squamous cell carcinoma provides a 5-year global survival rate of 69.4%, compared to 56.2% for conventional methods.

In gastric cancer treatment, data from Japan indicates that robotic gastrectomies reduce blood loss by 33-40% and significantly lower the risk of converting to open surgery. Similarly, in Italy, the Ospedale di Circolo in Varese has successfully performed its first total robotic gastrectomy, marking a milestone in minimally invasive oncological care.

The field of cardiac surgery is also seeing a shift. The Da Vinci 5 system has received extended CE marking in Europe, allowing its use in certain adult cardiac procedures such as thoracoscopic-assisted cardiotomies and minimally invasive coronary artery bypasses. Experts note that while robots enhance surgical precision and vision, they serve as tools to augment, rather than replace, the surgeon.